［1］ Morgenstern DA,London WB,Stephens D,et al.Metastatic neuroblastoma confined to distant lymph nodes(stage 4N)predictsoutcome in patients with stage 4 disease:a study from the International Neuroblastoma Risk Group Database［J］.J Clin Oncol,2014,32(12):1228-1235.
［2］ He J,Zou Y,Wang T,et al.Genetic variations of GWAS-identified genes and neuroblastoma susceptibility:a replication study in southern Chinese children［J］.Transl Oncol,2017,10(6):936-941.
［3］ Liang J,Tong P,Zhao W,et al.The REST gene signature predicts drug sensitivity in neuroblastoma cell lines and is significantly associated with neuroblastoma tumor stage［J］.Int J Mol Sci,2014,15 (7):11220-11233.
［4］ Hender TO,Bhatia S,Pinto N,et al.Racial and ethnic disparities in risk and survival in children with neuroblastma:a Children's Oncology Group study［J］.J Clin Oncol,2011,29:76-82.
［5］ Whittle SB,Smith V,Doherty E,et al.Overview and recent advances in the treatment of neuroblastoma［J］.Expert Rev Anticancer Ther,2017,17(4):369-386.
［6］ Alvarado CS,London WB,Look AT,et al.Natural history and biology of stage A neuroblastma:a Pediatric Oncology Group Study ［J］.J Pediatr Hematol Oncol,2000,22(3):197-205.
［7］Davidoff AM.Neuroblastoma［J］.Semin Padiatr Surg,2012,21(1):2-14.
［8］Baker DL,Schmidt ML,Cohn SL,et al.Outcome sfter reduced chemotherapy for intermediate-risk neuroblastoma ［J］.N Engl J Med,2010,363(14):1313-1323.
［9］Thompson D,Vo KT,London WB,et al.Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma:a report from the Intemational Neuroblastoma Risk Group project［J］.Cancer,2016,122:935-945.
［10］ Lee GY,Chun YS,Shin HW,et al.Potential role of the N-MYC downstream-regulated gene family in reprogramming cancer metabolism under hypoxia［J］.Oncotarget,2016,7(35):57442-57451.
［11］ Waters AM,Beierle EA.The interaction between FAK,MYCN,p53 and Mdm2 in neuroblastma［J］.Anticancer Agents Med Chem,2014,14(1):46-51.
［12］ Zheng J,Dong W,Zhang J,et al.YB-1,a new biomarker of glioma progression,is associated with the prognosis of glioma patients［J］.Acta Biochim Biophys Sin (Shanghai),2016,48(4):318-325.
［13］ Valentijn LJ,Koppen A,van Asperen R,et al.Inhibition of a new differentiation pathway in neuroblastma by copy number defects of N-myc,Cdc42,and NM23 genes［J］.Cancer Res,2005,65(8):3136-3145.
［14］ Xiao D,Ren P,Su H,et al.Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2［J］.Oncotarget,2015,6(38):40655-40666.
［15］ Ribeiro D,Klarqvist MD,Weatermark UK,et al.Regulation of nuclear hormone reseptors by MYCN-driven miRNAs impacts neural differentitation and survival in neuroblastoma patients［J］.Cell Rep,2016,16(4):979-993.
［16］ Jordan KR,Kapoor P,Spongberg E,et al.Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients［J］.Cancer Immunol Immunother,2017,66(4):503-513.
［17］Rojas Y,Jaramillo S,Lyons K,et al.The optimai timing of surgical resection in high-risk neuroblastoma［J］.J Pediatr Surg,2016,S0022-3468(16):30110-30115.
［18］ Kreissman SG,Villablanca JG,Diller L,et al.Respnse and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastma(HR-NB):a Children's Oncology Group(COG A3973) study［J］.J Clin Oncol,2007,25:95-105.
［19］ De Kraker J,Hoefnagel CA,Verschuur AC,et al.Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastma patients over 1 year of age［J］.Eur J Cancer,2008,44:551-556.